Navigation Links
Sparking Growth In Ontario's Biopharmaceutical Industry

Support For Cutting-Edge Health Research Will Create Jobs, Attract


TORONTO, Feb. 4 /PRNewswire/ - The Ontario government is providing $150 million through the Next Generation Jobs Fund to encourage research-based pharmaceutical companies to invest in Ontario, Minister of Research and Innovation John Wilkinson has announced.

"Attracting these investments will create good-paying jobs that support the discovery of new medical treatments for diseases that affect us all," said Wilkinson. "Supporting this research will strengthen Ontario's economy and create a higher quality of life for Ontario families."

The biopharmaceutical industry:

- Employs over 9,000 Ontarians in high-value jobs, such as researchers

and scientists

- Invested more than $550-million in Ontario in 2006 to enable the

discovery of life-saving therapies, such as antibiotics, new vaccines

and more effective cancer treatments

- Makes up thirty-one of Canada's top 100 corporate R&D investors.

The $150 million will create jobs in the biopharmaceutical research community by enabling companies to apply for grants, loans, forgivable interest loans and funds for building infrastructure, research and training.

"Our government's $150 million investment is focused on increasing the amount of health research and advanced manufacturing activity that is happening right here in Ontario," said Minister of Economic Development and Trade Sandra Pupatello. "The significant investments that biopharmaceutical companies make in health research are essential to the growth and success of our emerging biotechnology industry, and other sectors that are important to Ontario's economy."

The $1.15-billion Next Generation Jobs Fund supports job creation in areas where Ontario has a strong competitive advantage and is designed to build and strengthen industry, create jobs and make Ontario globally competitive in key sectors.

"Today's announcement sends a signal not only to the domestic biopharmaceutical industry, but also to our global community that Ontario values this sector and its potential for growth," said Ronnie Miller, Chairman of Rx&D and President & CEO Hoffmann-La Roche Limited. "By working together with the Ontario government, our community is setting a course for the future that will help ensure we can continue to invest today in the medical discoveries of tomorrow, retain our brightest minds here at home and ultimately, ensure patients benefit from access to these new medicines and vaccines."

"Ontario enjoys a vibrant, world-class health research sector," said Janet Rossant, Chief of Research, The Hospital for Sick Children. "Incentives like this new biopharmaceutical investment program will ensure that partnerships between industry and researchers in Ontario continue to build a strong knowledge-based economy that will create jobs and improve the health of our population."

The $150-million biopharmaceutical investment program is just one of the ways the Ontario government is strengthening the economy and supporting Ontario families. Other initiatives include:

- Encouraging strong job creation, with over 417,000 net new jobs since

October 2003

- Launching the $160 million Ideas-to-Market strategy that supports

emerging companies

- Helping Ontario's brightest researchers move their new ideas from

labs to the global marketplace by investing $527 million over five

years in the Ontario Research Fund

- Establishing a six-year, $500-million Advanced Manufacturing

Investment Strategy to help manufacturers invest in innovative new


- Providing a 21 per cent Capital Tax rate cut for all businesses

retroactive to January 1, 2007, on the way to full elimination in


- Eliminating the Capital Tax on January 1, 2008 for corporations

primarily engaged in manufacturing and resource activities and

- Announcing in the 2007 Fall Economic Statement an additional

$50 million in strategic investment to further strengthen Ontario's

environment for scientific research that will lead to new

discoveries, higher quality of life and new jobs.

SOURCE Ontario Ministry of Economic Development and Trade
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
2. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
3. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
4. STALLERGENES : Strong Business Growth: +17% and Earnings Per Share up 30%
5. Monogram Biosciences to Present at the ThinkEquity Partners Fifth Annual Growth Conference
6. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
7. Sigma-Aldrich Expansion in Republic of China to Support SAFC Growth
8. Bionovo to Present at A.G. Edwards 2nd Annual Emerging Growth Conference 2007
9. Kensey Nash to Present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum Conference
10. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
11. ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners Fifth Annual Growth Conference
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... quality, regulatory and technical consulting, provides a free webinar on Performing ... July 13, 2016 at 12pm CT at no charge. , Incomplete investigations are ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016 On Monday, the ... to industry to share solutions for the Biometric Exit ... Customs and Border Protection (CBP), explains that CBP intends ... departing the United States , in ... to defeat imposters. Logo - ...
(Date:6/20/2016)... 20, 2016 Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring announced ... it has secured the final acceptance by all ... Managed Access Systems (MAS) installed. Furthermore, Securus will ... be installed by October, 2016. MAS distinguishes between ...
(Date:6/15/2016)... ALBANY, New York , June 15, 2016 ... published a new market report titled "Gesture Recognition Market ... Trends and Forecast, 2016 - 2024". According to the ... at USD 11.60 billion in 2015 and is ... and reach USD 48.56 billion by 2024.  ...
Breaking Biology News(10 mins):